Table 1. The combination of crude components of SCRT Latin nameAmount (g)Company of purchaseSource Ephedrae Herba5.625KwangmyungdangChina Paeoniae Radix5.625KwangmyungdangUiseong,

Slides:

Advertisements

Similar presentations

Supplementary Figure S1.

Advertisements

Basic Aspects and Most Commonly Worldwide Employed and Validated In Vitro Assays Leon F. Stankowski, Jr., PhD Consultant, Genetic Toxicology Genotoxicity.

BEL7402Huh7 C Tet Rapa C Tet Rapa LC3-II LC3-I GAPDH Figure S1 Detecting Tetrandrine-induced autophagy in Huh7 and BEL7402 cell lines. Rapamycin treatment.

CA-1 Preclinical Studies Philip Bentley, PhD Vice President Toxicology/Pathology Novartis Pharmaceuticals Corporation Philip Bentley, PhD Vice President.

Materials and Methods Phase 1 Evaluated acute effects on fasting blood glucose and on post-oral glucose Groups 1 and 3 received distilled water Groups.

August 24-26, 2015 Philadelphia, USA

Kamala Pant, M.S. BioReliance Study Director/Principal Scientist

General Linear Model.

Validation Defination Establishing documentary evidence which provides a high degree of assurance that specification process will consistently produce.

Figure S1. (a) Western blot of purified recombinant truncated His-hTAF and His-Fiber as detected by anti-His antibody. His-hTAF was verified.

LAB. S2: Spectrophotometric Determination of Indomethacin/Salicylic Acid Mixture.

Removal Effects of Heavy Metals (As, Cd, Pb, Hg) in Herbal Medicines by Washing KIM Dong-Gyu*, HAN Eun-Jung, JUNG Sam-Joo, HAN Chang-Ho, KIM Ouk-Hee, KWAK.

Lab S1 Spectrophotometric Determination of Ferrous Ion.

© The Author(s) Published by Science and Education Publishing.

Chronic exposure to exogenous glucocorticoids primes microglia to pro-inflammatory stimuli and induces NLRP3 mRNA in the hippocampus Matthew G. Frank,

Quantitative tests for proteins

EVALUATION OF THE POTENTIAL IN VIVO GENOTOXICITY OF QUERCETIN

Fig. 1 Pathways for the biosynthesis of N-p-coumaroyloctopamine (p-CO) and chlorogenic acid (CGA) in potato tuber tissue. PAL, phenylalanine ammonia-lyase;

Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum by Cristina Bergamaschi, Jenifer Bear, Margherita Rosati,

Quantitative tests for proteins

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Supplementary Figure S13

Molecular Therapy - Nucleic Acids

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

E. Cendejas-Bueno, A. Forastiero, J. L. Rodriguez-Tudela, M

Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.

LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio.

Volume 118, Issue 1, Pages (January 2000)

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

Quantitative tests for proteins

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

ALT-803 administration increases peripheral blood cell counts of lymphocyte subsets in cynomolgus monkeys. ALT-803 administration increases peripheral.

DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.

Figure S4 A C Vehicle control AC0010 (300mg/kg) Gefitinib (50mg/kg) D

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

E. Cendejas-Bueno, A. Forastiero, J. L. Rodriguez-Tudela, M

A Novel Mechanism of EML4-ALK Rearrangement Mediated by Chromothripsis in a Patient-Derived Cell Line Tatsushi Kodama, MS, Noriko Motoi, MD, PhD, Hironori.

2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia by Elizabeth Tkaczynski, Abinaya Arulselvan, John Tkaczynski,

Results of the PE tubes phantom experiments.

Masanobu Ishii et al. BTS 2017;2:

by Nicholas J. Laping, Michael P. DeMartino, Joshua E

PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:

Effect of MI-773 and/or cisplatin in a preclinical model of ACC

Valproic acid (VPA) prevents small cell lung carcinoma (SCLC) tumour growth in combination with cyclophosphamide, vindesine and doxorubicin. Valproic acid.

Effect of MI-773 dosing on long-term efficacy.

Correlations between indices of oxidative status and individual condition. Correlations between indices of oxidative status and individual condition. Lines.

MicroPET and CCD imaging of β-cells in MIP-TF mice.

Regression and Correlation of Data

First order kinetic demonstrated by the logarithm of the dobutamine concentration in CIVAS syringes as a function of time, where (♦) represents 4°C (protected.

Effects of rhein on FBG (A) and glucose intolerance (B) in db/db mice.

GR cells are dependent upon sustained CDC25C signaling as pharmacologic or genetic inhibition of CDC25C induce synthetic lethality. GR cells are dependent.

IL-6 production with increasing doses of endotoxin.

Tlr4−/− attenuates symptomatic parameters of gut toxicity: diarrhea and weight loss. Tlr4−/− attenuates symptomatic parameters of gut toxicity: diarrhea.

The effects of IAA and glycyrrhizin (Gc) on proliferation and cell-cycle distribution. The effects of IAA and glycyrrhizin (Gc) on proliferation and cell-cycle.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo). Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo).

A, decreased vessel formation in basic fibroblast growth factor–supplemented Matrigel plugs excised from mice 10 days after treatment with the combination.

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer cell growth. Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer.

Serum IFNγ and immune responses following tecemotide/cisplatin combination treatment in a urethane-induced hMUC1.Tg lung cancer mouse model. Serum IFNγ.

PDL192 and inhibit the growth of xenograft tumors.

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

Plasma concentration-time profile after oral administration of a single dose. Plasma concentration-time profile after oral administration of a single dose.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

CPI-444 synergizes with anti–PD-L1 and anti–CTLA-4 treatment.

European Urology Oncology

DHA and dietary n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in xenograft models. DHA and dietary n-3 PUFAs inhibit endometrial cancer.

Presentation transcript:

Table 1. The combination of crude components of SCRT Latin nameAmount (g)Company of purchaseSource Ephedrae Herba5.625KwangmyungdangChina Paeoniae Radix5.625KwangmyungdangUiseong, Korea Schisandrae Fructus5.625KwangmyungdangSamcheok, Korea Pinelliae Tuber5.625KwangmyungdangChina Asiasari Radix3.75KwangmyungdangChina Zingiberis Rhizoma Crudus3.75KwangmyungdangUlsan, Korea Cinnamomi Ramulus3.75KwangmyungdangVietnam Glycyrrhizae Radix et Rhizoma3.75KwangmyungdangChina Total37.50

Table 2. Calibration curves of eight marker components (n=3). Component Linear range (  g/mL) Regression equation a Correlation coefficient (r 2 ) Albiflorin 0.78 – y = 11,446.68x – 9, Paeoniflorin 1.56 – y = 11,710.55x – 11, Liquiritin 0.78 – y = 15,742.58x – 4, Coumarin 0.39 – 50.00y = 44,991.78x – 11, Cinnamic acid 0.39 – 50.00y = 81,948.89x – 14, Cinnamaldehyde 0.39 – 50.00y = 12, x – 20, Glycyrrhizin 0.39 – 50.00y = 11,615.46x – 2, Schizandrin0.39 – 50.00y = 17,962.63x – 3, a y means peak area (mAU). x means concentration (  g/mL).

Table 3. Contents of eight components in the SCRT by HPLC (n=3). CompoundMean (mg/g)SDRSD (%) Albiflorin Paeoniflorin Liquiritin Coumarin Cinnamic acid Cinnamaldehyde Glycyrrhizin Schizandrin

Nominal conc. of SCRT (μg/mL) S9 mixTime hours a) Mean total aberrant metaphases Mean total aberrations Mean of PP+ER Relative cell counts (%) 6 h treatment (+S9) Vehicle control / Not counted /0.51.5/ /1.02.5/ * /5.5 ** 8.0/ ** 74 Positive control (CPA 6) /12.0 ** 15.5/ h treatment (-S9) Vehicle control / / / /8.0 ** 13.0/ * Not counted35 Positive control (EMS 800) /18.5 ** 31.0/ h treatment (-S9) Vehicle control /0.01.0/ / /1.01.5/ /5.5 ** 9.5/ * Not counted Not counted32 Positive control (EMS 600) /23.5 ** 37.0/ Table 4. Chromosome aberration assay and relative cell counts of SCRT. *, ** Significantly different from the control at P<0.05 and P<0.01, respectively a) Treatment time-recovery time

Nominal conc. of SCRT (μg/mL) S9 mix Time hours a) Mean total aberrant metaphases Mean total aberrations Mean of PP+ER Relative cell counts (%) 6 h treatment (+S9) / Not counted /0.51.5/ /1.02.5/ * /5.5 ** 8.0/ ** 74 CPA /12.0 ** 15.5/ h treatment (-S9) / / / /8.0 ** 13.0/ * Not counted35 EMS /18.5 ** 31.0/ h treatment (-S9) /0.01.0/ / /1.01.5/ /5.5 ** 9.5/ * Not counted Not counted32 EMS /23.5 ** 37.0/ Table 4. Chromosome aberration assay and relative cell counts of SCRT. **Significantly different from the control at P<0.01 a) Treatment time-recovery time

Table 5. Body weight changes of Micronucleus test in mice following administration of SCRT Group Vehicle control (DW) SCRT Positive control (CPA) Dose (mg/kg) Day 1 (Mean ± S.D)34.3 ± ± ± ± ± 0.66 Day 2 (Mean ± S.D)34.3 ± ± ± ± ± 1.15 Day 3 (Mean ± S.D)34.6 ± ± ± ± ± 1.23 CPA: cyclophosphamide monohydrate, DW: distilled water

Table 6. Micronucleus test in mice following a single oral dose of SCRT GroupVehicle control SCRT Positive control Dose (mg/kg) MNPCE/2000PCEs (Mean ± S.D) 1.67 ± ± ± ± * ± PCE/(PCE+NCE) (Mean ± S.D) 0.55 ± ± ± ± ± 0.02 Number of animals33333 MNPCE: PCE with one or more micronuclei; PCE: Polychromatic erythrocyte; NCE: Normochromatic erythrocyte * Significantly different from the control at p<0.05